Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Celularity Inc.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.

Dragasac Limited

Sorrento Therapeutics

Starr Insurance Companies

Alumni Ventures

Heritage Group

Human Longevity

Section 32 Celgene

United Therapeutics

Bill Maris

Tony Robbins

We're excited for the future here at Celularity and are off to an invigorating 2024! Net sales expectations and updates can be found in the full release, linked below.

Exciting announcement! The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.

Excited about the future at Celularity!
https://lnkd.in/gmJmRJCP

We're pleased to have had our Chairman, CEO and Founder, Dr. Bob Hariri, featured by Cell & Gene .  Discussion topics included lessons learned in allogeneic cell therapy, advice for allogeneic cell therapy start-ups, the strategy behind the Celularity facility, and more. 
#celltherapy #cellandgenetherapy 
https://lnkd.in/dj2Sr_3c

We’re pleased to announce our exclusive U.S. commercialization agreement with Verséa Health (Verséa Ophthalmics), which will allow us to support eye care professionals as they treat ocular surface diseases and perform certain ocular surgeries. Discover more about the partnership: https://bit.ly/3YcZdOM

Next Wednesday, July 26, our team will present data on Celularity’s proprietary #biomaterials at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE) in Osaka, Japan.

Presented by Anna Gosiewska, PhD, the data will include three benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products. Find out more about the data here: https://bit.ly/3JY4LXS

Check out this interview with our Chairman, CEO and Founder, Dr. Bob Hariri, in the latest issue of Pulse 2.0
https://lnkd.in/ejr2bu6X

Next month, Celularity will present at the 7th International Conference on Orthopedics in Rome. The oral session will share data from a new technology in development for orthopedic applications.
 
Read the full announcement to learn more about the study: https://bit.ly/3NpgMGA

Exciting update: data featured in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor (TF) gene knock out (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower TF expression, activity, and thrombotic effects. This #preclinical #data from an edited version of one of our cell therapy candidates signals a feasible pathway to potentially improve the safety of ASC-based #celltherapy.
 
Full details here: https://bit.ly/3qjvHua

Today, we are excited to announce that we have received a $45 million purchase order for Celularity private label Halal-Certified #biomaterial products from Jamjoom Medicine Store.
 
This marks the first purchase order received under our recently announced expansion into the Middle East market, as part of our global market strategy. Read the full announcement: https://bit.ly/426nqXw

COM:CELULARITY

Celularity Inc.

Last Close

2.85

22/11 21:00

Market Cap

61.43M

Beta: -

Volume Today

104.87K

Avg: -

Financials Not Available